Hydroxyurea Capsules 500 mg and Raptiva
Determining the interaction of Hydroxyurea Capsules 500 mg and Raptiva and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using efalizumab together with hydroxyurea may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.
- "Product Information. Raptiva (efalizumab)." Genentech, South San Francisco, CA.
Generic Name: hydroxyurea
Brand name: Droxia, Hydrea, Mylocel, Siklos
Synonyms: Hydroxyurea
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Hydroxyurea Capsules 500 mg-Rasagiline
- Hydroxyurea Capsules 500 mg-Rasagiline Mesylate
- Hydroxyurea Capsules 500 mg-Rasburicase
- Hydroxyurea Capsules 500 mg-Rasburicase Intravenous
- Hydroxyurea Capsules 500 mg-Rash Relief Antifungal
- Hydroxyurea Capsules 500 mg-Rasuvo
- Raptiva-Hydroxyurea Tablets
- Raptiva-Hydroxyzine
- Raptiva-Hydroxyzine Capsules
- Raptiva-Hydroxyzine Capsules and Tablets
- Raptiva-Hydroxyzine Hydrochloride
- Raptiva-Hydroxyzine Injection